Literature DB >> 19789694

Capecitabine-induced cardiotoxicity mimicking myocardial infarction.

T Sentürk1, O Kanat, T Evrensel, A Aydinlar.   

Abstract

Capecitabine, a fluoropyrimidine derivative, is an orally administered drug that delivers 5-fluorouracil (5-FU) selectively to the tumour. The drug has demonstrated activity in metastatic colorectal cancer. We describe a male patient receiving capecitabine therapy with typical chest pain and electrocardiographic changes consistent with STsegment elevation myocardial infarction. Capecitabine-induced cardiotoxicity may develop in patients who have had a previous episode of 5-FU-induced cardiotoxicity. Capecitabine-induced cardiotoxicity is a rare condition that may lead to diagnostic and therapeutic dilemmas. (Neth Heart J 2009;17:277-80.).

Entities:  

Year:  2009        PMID： 19789694      PMCID： PMC2743815          DOI： 10.1007/BF03086265

Source DB:  PubMed          Journal:  Neth Heart J        ISSN： 1568-5888            Impact factor:   2.380


  16 in total

1.  [Coronary insufficiency after an oral intake of capecitabine].

Authors:  J Desramé; J A Bronstein; C Thiolet; C Bredin; B Ceccaldi; B Vergeau; O Farret
Journal:  Gastroenterol Clin Biol       Date:  2001 Aug-Sep

2.  Prophylaxis of 5-fluorouracil-induced coronary vasospasm with calcium channel blockers.

Authors:  L Oleksowicz; H W Bruckner
Journal:  Am J Med       Date:  1988-11       Impact factor: 4.965

Review 3.  Capecitabine: effective oral fluoropyrimidine chemotherapy.

Authors:  Joseph McKendrick; John Coutsouvelis
Journal:  Expert Opin Pharmacother       Date:  2005-06       Impact factor: 3.889

4.  Cardiac disturbances during the administration of taxol.

Authors:  E K Rowinsky; W P McGuire; T Guarnieri; J S Fisherman; M C Christian; R C Donehower
Journal:  J Clin Oncol       Date:  1991-09       Impact factor: 44.544

5.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

Review 6.  Cardiotoxicity of the antiproliferative compound fluorouracil.

Authors:  K Becker; J F Erckenbrecht; D Häussinger; T Frieling
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

Review 7.  Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.

Authors:  V B Pai; M C Nahata
Journal:  Drug Saf       Date:  2000-04       Impact factor: 5.606

8.  Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin.

Authors:  T Kuzel; B Esparaz; D Green; M Kies
Journal:  Cancer       Date:  1990-02-15       Impact factor: 6.860

Review 9.  Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer.

Authors:  Antona J Wagstaff; Tim Ibbotson; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

Authors:  E L Trimble; J D Adams; D Vena; M J Hawkins; M A Friedman; J S Fisherman; M C Christian; R Canetta; N Onetto; R Hayn
Journal:  J Clin Oncol       Date:  1993-12       Impact factor: 44.544
View more
  8 in total

1.  Case histories: increasing role for major journals.

Authors:  E E van der Wall; A A M Wilde
Journal:  Neth Heart J       Date:  2009-08       Impact factor: 2.380

Review 2.  The effects of exercise on cardiovascular outcomes before, during, and after treatment for breast cancer.

Authors:  Kathleen M Sturgeon; Bonnie Ky; Joseph R Libonati; Kathryn H Schmitz
Journal:  Breast Cancer Res Treat       Date:  2013-12-14       Impact factor: 4.872

Review 3.  Cardiovascular complications of metastatic colorectal cancer treatment.

Authors:  Kalliopi Keramida; Georgios Charalampopoulos; Dimitrios Filippiadis; Elias Tsougos; Dimitrios Farmakis
Journal:  J Gastrointest Oncol       Date:  2019-08

Review 4.  Preparation and Evaluation of Animal Models of Cardiotoxicity in Antineoplastic Therapy.

Authors:  Chenchen Meng; Lu Fan; Xiaoming Wang; Yunjiao Wang; Yanyang Li; Shuchao Pang; Shichao Lv; Junping Zhang
Journal:  Oxid Med Cell Longev       Date:  2022-07-05       Impact factor: 7.310

5.  Capecitabine-induced cardiotoxicity mimicking myocardial infarction.

Authors:  T Sentürk; O Kanat; T Evrensel; A Aydinlar
Journal:  Neth Heart J       Date:  2009-08       Impact factor: 2.380

Review 6.  Chemotherapeutic-Induced Cardiovascular Dysfunction: Physiological Effects, Early Detection-The Role of Telomerase to Counteract Mitochondrial Defects and Oxidative Stress.

Authors:  Nabeel Quryshi; Laura E Norwood Toro; Karima Ait-Aissa; Amanda Kong; Andreas M Beyer
Journal:  Int J Mol Sci       Date:  2018-03-10       Impact factor: 5.923

Review 7.  Myocardial Ischemia Related to Common Cancer Therapy-Prevention Insights.

Authors:  Minerva Codruta Badescu; Oana Viola Badulescu; Dragos Viorel Scripcariu; Lăcrămioara Ionela Butnariu; Iris Bararu-Bojan; Diana Popescu; Manuela Ciocoiu; Eusebiu Vlad Gorduza; Irina Iuliana Costache; Elena Rezus; Ciprian Rezus
Journal:  Life (Basel)       Date:  2022-07-12

Review 8.  5-FU induced cardiotoxicity: case series and review of the literature.

Authors:  Cai Yuan; Hiral Parekh; Carmen Allegra; Thomas J George; Jason S Starr
Journal:  Cardiooncology       Date:  2019-09-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.